XML 33 R18.htm IDEA: XBRL DOCUMENT
v3.19.1

Segments of Business and Geographic Areas | 3 Months Ended
--- | ---
Mar. 31, 2019
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS
|  |  | Fiscal First Quarters Ended
(Dollars in Millions) |  |  | March 31, 2019 |  | April 1, 2018 |  | Percent Change
CONSUMER |  |  |  |  |  |  |
Baby Care |  |  |  |  |  |  |
U.S. |  |  | $ | 87 |  |  | 97 |  |  | (10.9 | )%
International |  |  | 307 |  |  | 360 |  |  | (14.8 | )
Worldwide |  |  | 394 |  |  | 457 |  |  | (14.0 | )
Beauty |  |  |  |  |  |  |
U.S. |  |  | 588 |  |  | 611 |  |  | (3.8 | )
International |  |  | 502 |  |  | 473 |  |  | 6.2 |
Worldwide |  |  | 1,090 |  |  | 1,084 |  |  | 0.6 |
Oral Care |  |  |  |  |  |  |
U.S. |  |  | 151 |  |  | 157 |  |  | (3.5 | )
International |  |  | 216 |  |  | 222 |  |  | (2.8 | )
Worldwide |  |  | 367 |  |  | 379 |  |  | (3.1 | )
OTC |  |  |  |  |  |  |
U.S. |  |  | 507 |  |  | 465 |  |  | 9.1 |
International |  |  | 580 |  |  | 607 |  |  | (4.6 | )
Worldwide |  |  | 1,087 |  |  | 1,072 |  |  | 1.3 |
Women's Health |  |  |  |  |  |  |
U.S. |  |  | 3 |  |  | 3 |  |  | 4.2 |
International |  |  | 222 |  |  | 240 |  |  | (7.5 | )
Worldwide |  |  | 225 |  |  | 243 |  |  | (7.3 | )
Wound Care/Other |  |  |  |  |  |  |
U.S. |  |  | 102 |  |  | 103 |  |  | (0.9 | )
International |  |  | 53 |  |  | 60 |  |  | (11.6 | )
Worldwide |  |  | 155 |  |  | 163 |  |  | (4.8 | )
TOTAL CONSUMER |  |  |  |  |  |  |
U.S. |  |  | 1,438 |  |  | 1,436 |  |  | 0.2 |
International |  |  | 1,880 |  |  | 1,962 |  |  | (4.2 | )
Worldwide |  |  | 3,318 |  |  | 3,398 |  |  | (2.4 | )
PHARMACEUTICAL |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |
U.S. |  |  | 2,163 |  |  | 2,000 |  |  | 8.1 |
International |  |  | 1,088 |  |  | 1,042 |  |  | 4.5 |
Worldwide |  |  | 3,251 |  |  | 3,042 |  |  | 6.9 |
REMICADE® |  |  |  |  |  |  |
U.S. |  |  | 774 |  |  | 916 |  |  | (15.5 | )
U.S. Exports |  |  | 76 |  |  | 142 |  |  | (46.4 | )
International |  |  | 252 |  |  | 331 |  |  | (23.6 | )
Worldwide |  |  | 1,102 |  |  | 1,389 |  |  | (20.6 | )
SIMPONI / SIMPONI ARIA® |  |  |  |  |  |  |
U.S. |  |  | 263 |  |  | 224 |  |  | 17.0 |
International |  |  | 261 |  |  | 294 |  |  | (11.1 | )
Worldwide |  |  | 524 |  |  | 518 |  |  | 1.0 |
STELARA® |  |  |  |  |  |  |
U.S. |  |  | 882 |  |  | 652 |  |  | 35.2 |
International |  |  | 523 |  |  | 409 |  |  | 27.9 |
Worldwide |  |  | 1,405 |  |  | 1,061 |  |  | 32.4 |
TREMFYA® |  |  |  |  |  |  |
U.S. |  |  | 168 |  |  | 66 |  |  | *
International |  |  | 49 |  |  | 6 |  |  | *
Worldwide |  |  | 217 |  |  | 72 |  |  | *
OTHER IMMUNOLOGY |  |  |  |  |  |  |
U.S. |  |  | — |  |  | — |  |  | —
International |  |  | 3 |  |  | 2 |  |  | 19.5
Worldwide |  |  | 3 |  |  | 2 |  |  | 19.5
Infectious Diseases |  |  |  |  |  |  |
U.S. |  |  | 357 |  |  | 333 |  |  | 7.3 |
International |  |  | 489 |  |  | 497 |  |  | (1.7 | )
Worldwide |  |  | 846 |  |  | 830 |  |  | 1.9 |
EDURANT® / rilpivirine |  |  |  |  |  |  |
U.S. |  |  | 12 |  |  | 14 |  |  | (18.8 | )
International |  |  | 199 |  |  | 196 |  |  | 2.2 |
Worldwide |  |  | 211 |  |  | 210 |  |  | 0.8 |
PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |  |  |  |
U.S. |  |  | 315 |  |  | 273 |  |  | 15.5 |
International |  |  | 208 |  |  | 205 |  |  | 1.5 |
Worldwide |  |  | 523 |  |  | 478 |  |  | 9.5 |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |
U.S. |  |  | 30 |  |  | 46 |  |  | (33.8 | )
International |  |  | 82 |  |  | 96 |  |  | (16.0 | )
Worldwide |  |  | 112 |  |  | 142 |  |  | (21.7 | )
Neuroscience |  |  |  |  |  |  |
U.S. |  |  | 723 |  |  | 624 |  |  | 16.0 |
International |  |  | 905 |  |  | 935 |  |  | (3.2 | )
Worldwide |  |  | 1,629 |  |  | 1,559 |  |  | 4.5 |
CONCERTA® / Methylphenidate |  |  |  |  |  |  |
U.S. |  |  | 97 |  |  | 66 |  |  | 47.7 |
International |  |  | 116 |  |  | 107 |  |  | 8.5 |
Worldwide |  |  | 214 |  |  | 173 |  |  | 23.4 |
INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |  |  |  |  |  |
U.S. |  |  | 483 |  |  | 400 |  |  | 20.7 |
International |  |  | 307 |  |  | 296 |  |  | 3.8 |
Worldwide |  |  | 790 |  |  | 696 |  |  | 13.5 |
RISPERDAL CONSTA® |  |  |  |  |  |  |
U.S. |  |  | 77 |  |  | 82 |  |  | (6.8 | )
International |  |  | 102 |  |  | 114 |  |  | (10.3 | )
Worldwide |  |  | 179 |  |  | 196 |  |  | (8.8 | )
OTHER NEUROSCIENCE |  |  |  |  |  |  |
U.S. |  |  | 66 |  |  | 76 |  |  | (12.0 | )
International |  |  | 379 |  |  | 418 |  |  | (9.2 | )
Worldwide |  |  | 446 |  |  | 494 |  |  | (9.6 | )
Oncology |  |  |  |  |  |  |
U.S. |  |  | 962 |  |  | 933 |  |  | 3.1 |
International |  |  | 1,556 |  |  | 1,378 |  |  | 13.0 |
Worldwide |  |  | 2,518 |  |  | 2,311 |  |  | 9.0 |
DARZALEX® |  |  |  |  |  |  |
U.S. |  |  | 352 |  |  | 264 |  |  | 33.0 |
International |  |  | 277 |  |  | 168 |  |  | 65.1 |
Worldwide |  |  | 629 |  |  | 432 |  |  | 45.5 |
IMBRUVICA® |  |  |  |  |  |  |
U.S. |  |  | 349 |  |  | 227 |  |  | 53.7 |
International |  |  | 435 |  |  | 360 |  |  | 20.8 |
Worldwide |  |  | 784 |  |  | 587 |  |  | 33.5 |
VELCADE® |  |  |  |  |  |  |
U.S. |  |  | — |  |  | — |  |  | — |
International |  |  | 263 |  |  | 313 |  |  | (16.0 | )
Worldwide |  |  | 263 |  |  | 313 |  |  | (16.0 | )
ZYTIGA® / abiraterone acetate |  |  |  |  |  |  |
U.S. |  |  | 185 |  |  | 407 |  |  | (54.5 | )
International |  |  | 494 |  |  | 438 |  |  | 12.9 |
Worldwide |  |  | 679 |  |  | 845 |  |  | (19.6 | )
OTHER ONCOLOGY |  |  |  |  |  |  |
U.S. |  |  | 76 |  |  | 35 |  |  | * |
International |  |  | 87 |  |  | 99 |  |  | (12.2 | )
Worldwide |  |  | 163 |  |  | 134 |  |  | 21.7 |
Pulmonary Hypertension |  |  |  |  |  |  |
U.S. |  |  | 430 |  |  | 361 |  |  | 19.2 |
International |  |  | 226 |  |  | 224 |  |  | 0.7 |
Worldwide |  |  | 656 |  |  | 585 |  |  | 12.1 |
OPSUMIT® |  |  |  |  |  |  |
U.S. |  |  | 172 |  |  | 149 |  |  | 15.9 |
International |  |  | 133 |  |  | 122 |  |  | 8.9 |
Worldwide |  |  | 306 |  |  | 271 |  |  | 12.7 |
TRACLEER® |  |  |  |  |  |  |
U.S. |  |  | 61 |  |  | 68 |  |  | (10.1 | )
International |  |  | 56 |  |  | 72 |  |  | (22.9 | )
Worldwide |  |  | 117 |  |  | 140 |  |  | (16.7 | )
UPTRAVI® |  |  |  |  |  |  |
U.S. |  |  | 176 |  |  | 124 |  |  | 41.4 |
International |  |  | 22 |  |  | 16 |  |  | 42.8 |
Worldwide |  |  | 198 |  |  | 140 |  |  | 41.6 |
OTHER |  |  |  |  |  |  |
U.S. |  |  | 21 |  |  | 20 |  |  | 3.6 |
International |  |  | 15 |  |  | 14 |  |  | 4.6 |
Worldwide |  |  | 35 |  |  | 34 |  |  | 4.0 |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |
U.S. |  |  | 947 |  |  | 1,103 |  |  | (14.1 | )
International |  |  | 398 |  |  | 414 |  |  | (3.9 | )
Worldwide |  |  | 1,345 |  |  | 1,517 |  |  | (11.3 | )
XARELTO® |  |  |  |  |  |  |
U.S. |  |  | 542 |  |  | 578 |  |  | (6.3 | )
International |  |  | — |  |  | — |  |  | — |
Worldwide |  |  | 542 |  |  | 578 |  |  | (6.3 | )
INVOKANA® / INVOKAMET® |  |  |  |  |  |  |
U.S. |  |  | 154 |  |  | 204 |  |  | (24.8 | )
International |  |  | 49 |  |  | 44 |  |  | 11.6 |
Worldwide |  |  | 202 |  |  | 248 |  |  | (18.4 | )
PROCRIT® / EPREX® |  |  |  |  |  |  |
U.S. |  |  | 148 |  |  | 189 |  |  | (21.6 | )
International |  |  | 78 |  |  | 87 |  |  | (10.2 | )
Worldwide |  |  | 226 |  |  | 276 |  |  | (18.0 | )
OTHER |  |  |  |  |  |  |
U.S. |  |  | 104 |  |  | 132 |  |  | (21.3 | )
International |  |  | 271 |  |  | 283 |  |  | (4.4 | )
Worldwide |  |  | 374 |  |  | 415 |  |  | (9.7 | )
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |
U.S. |  |  | 5,582 |  |  | 5,354 |  |  | 4.3 |
International |  |  | 4,662 |  |  | 4,490 |  |  | 3.9 |
Worldwide |  |  | 10,244 |  |  | 9,844 |  |  | 4.1 |
MEDICAL DEVICES |  |  |  |  |  |  |
Diabetes Care |  |  |  |  |  |  |
U.S. |  |  | — |  |  | 117 |  |  | * |
International |  |  | — |  |  | 222 |  |  | * |
Worldwide |  |  | — |  |  | 339 |  |  | * |
Interventional Solutions |  |  |  |  |  |  |
U.S. |  |  | 343 |  |  | 304 |  |  | 12.6 |
International |  |  | 389 |  |  | 336 |  |  | 15.8 |
Worldwide |  |  | 732 |  |  | 640 |  |  | 14.3 |
Orthopaedics |  |  |  |  |  |  |
U.S. |  |  | 1,318 |  |  | 1,307 |  |  | 0.9 |
International |  |  | 885 |  |  | 943 |  |  | (6.2 | )
Worldwide |  |  | 2,204 |  |  | 2,250 |  |  | (2.1 | )
HIPS |  |  |  |  |  |  |
U.S. |  |  | 213 |  |  | 209 |  |  | 2.1 |
International |  |  | 148 |  |  | 154 |  |  | (3.8 | )
Worldwide |  |  | 361 |  |  | 363 |  |  | (0.4 | )
KNEES |  |  |  |  |  |  |
U.S. |  |  | 223 |  |  | 228 |  |  | (2.2 | )
International |  |  | 146 |  |  | 159 |  |  | (8.2 | )
Worldwide |  |  | 369 |  |  | 387 |  |  | (4.7 | )
TRAUMA |  |  |  |  |  |  |
U.S. |  |  | 417 |  |  | 407 |  |  | 2.5 |
International |  |  | 268 |  |  | 289 |  |  | (7.0 | )
Worldwide |  |  | 685 |  |  | 696 |  |  | (1.4 | )
SPINE & OTHER |  |  |  |  |  |  |
U.S. |  |  | 465 |  |  | 463 |  |  | 0.3 |
International |  |  | 323 |  |  | 341 |  |  | (5.5 | )
Worldwide |  |  | 788 |  |  | 804 |  |  | (2.2 | )
Surgery |  |  |  |  |  |  |
U.S. |  |  | 1,001 |  |  | 993 |  |  | 0.8 |
International |  |  | 1,394 |  |  | 1,430 |  |  | (2.6 | )
Worldwide |  |  | 2,395 |  |  | 2,423 |  |  | (1.2 | )
ADVANCED |  |  |  |  |  |  |
U.S. |  |  | 404 |  |  | 393 |  |  | 2.9 |
International |  |  | 576 |  |  | 573 |  |  | 0.5 |
Worldwide |  |  | 980 |  |  | 966 |  |  | 1.5 |
GENERAL |  |  |  |  |  |  |
U.S. |  |  | 425 |  |  | 423 |  |  | 0.3 |
International |  |  | 665 |  |  | 704 |  |  | (5.6 | )
Worldwide |  |  | 1,089 |  |  | 1,127 |  |  | (3.4 | )
SPECIALTY |  |  |  |  |  |  |
U.S. |  |  | 172 |  |  | 177 |  |  | (2.5 | )
International |  |  | 153 |  |  | 153 |  |  | (0.2 | )
Worldwide |  |  | 325 |  |  | 330 |  |  | (1.4 | )
Vision |  |  |  |  |  |  |
U.S. |  |  | 446 |  |  | 440 |  |  | 1.5 |
International |  |  | 682 |  |  | 675 |  |  | 1.1 |
Worldwide |  |  | 1,129 |  |  | 1,115 |  |  | 1.2 |
CONTACT LENSES / OTHER |  |  |  |  |  |  |
U.S. |  |  | 321 |  |  | 309 |  |  | 4.1 |
International |  |  | 502 |  |  | 498 |  |  | 1.0 |
Worldwide |  |  | 824 |  |  | 807 |  |  | 2.1 |
SURGICAL |  |  |  |  |  |  |
U.S. |  |  | 125 |  |  | 131 |  |  | (4.5 | )
International |  |  | 180 |  |  | 177 |  |  | 1.3 |
Worldwide |  |  | 305 |  |  | 308 |  |  | (1.1 | )
TOTAL MEDICAL DEVICES |  |  |  |  |  |  |
U.S. |  |  | 3,109 |  |  | 3,161 |  |  | (1.6 | )
International |  |  | 3,350 |  |  | 3,606 |  |  | (7.1 | )
Worldwide |  |  | 6,459 |  |  | 6,767 |  |  | (4.6 | )
WORLDWIDE |  |  |  |  |  |  |
U.S. |  |  | 10,129 |  |  | 9,951 |  |  | 1.8 |
International |  |  | 9,892 |  |  | 10,058 |  |  | (1.7 | )
Worldwide |  |  | $ | 20,021 |  |  | 20,009 |  |  | 0.1 | %
*Percentage greater than 100% or not meaningful EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
|  |  | Fiscal First Quarters Ended
(Dollars in Millions) |  |  | March 31, 2019 |  | April 1, 2018 |  | Percent Change
Consumer (1) |  |  | $ | 741 |  |  | 548 |  |  | 35.2 | %
Pharmaceutical(2) |  |  | 2,331 |  |  | 3,666 |  |  | (36.4 | )
Medical Devices(3) |  |  | 1,497 |  |  | 1,579 |  |  | (5.2 | )
Segment earnings before provision for taxes |  |  | 4,569 |  |  | 5,793 |  |  | (21.1 | )
Less: Expense not allocated to segments (4) |  |  | 147 |  |  | 312 |  |  |  |
Worldwide income before tax |  |  | $ | 4,422 |  |  | 5,481 |  |  | (19.3 | )%
(1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) Includes amortization expense of $0.1 billion and $0.1 billion in the fiscal first quarters of 2019 and 2018, respectively. (2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset, litigation expense of $0.3 billion and an unrealized gain on securities of $0.1 billion in the fiscal first quarter of 2019. Additionally, the fiscal first quarter of 2019 includes increased research and development expense primarily $0.3 billion related to an upfront payment to argenx and increased investment to advance the pipeline. Includes Actelion acquisition related costs of $0.1 billion in the fiscal first quarter of 2018. Includes amortization expense of $0.8 billion and $0.8 billion in the fiscal first quarters of 2019 and 2018, respectively. (3) Includes a restructuring related charge of $0.1 billion and $0.1 billion in the fiscal first quarters of 2019 and 2018, respectively. Includes litigation expense of $0.1 billion in the fiscal first quarter of 2019. Includes amortization expense of $0.2 billion and $0.3 billion in the fiscal first quarters of 2019 and 2018, respectively. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA
|  |  | Fiscal First Quarters Ended
(Dollars in Millions) |  |  | March 31, 2019 |  | April 1, 2018 |  | Percent Change
United States |  |  | $ | 10,129 |  |  | 9,951 |  |  | 1.8 | %
Europe |  |  | 4,609 |  |  | 4,797 |  |  | (3.9 | )
Western Hemisphere, excluding U.S. |  |  | 1,503 |  |  | 1,567 |  |  | (4.1 | )
Asia-Pacific, Africa |  |  | 3,780 |  |  | 3,694 |  |  | 2.3 |
Total |  |  | $ | 20,021 |  |  | 20,009 |  |  | 0.1 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration